CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting

Abstract Bispecific antibodies (BsAbs) represent an innovative class of off-the-shelf T-cell redirecting agents and are considered among the most promising immunotherapeutic strategies for the treatment of lymphoma. Notably, anti-CD20 × CD3 BsAbs have exhibited substantial monotherapy efficacy in pa...

Full description

Saved in:
Bibliographic Details
Main Authors: V. Tomarchio, L. Rigacci, O. Annibali
Format: Article
Language:English
Published: BMC 2025-04-01
Series:Journal of Hematology & Oncology
Online Access:https://doi.org/10.1186/s13045-025-01695-1
Tags: Add Tag
No Tags, Be the first to tag this record!